← FDA Drug Approvals (Drugs@FDA)
DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE
ANDA · Abbreviated New Drug Application (Generic) · Sponsor: MSN · Approved 2026-04-06
Drug application
- FDA Application #
ANDA211533- Application type
- Abbreviated New Drug Application (Generic)
- Brand name
- DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE
- Generic name
- DAPAGLIFLOZIN AND SAXAGLIPTIN
- Active ingredients
- DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
- Dosage form
- TABLET
- Route
- ORAL
- Marketing status
- Prescription
- Sponsor
- MSN
- Manufacturer
- Novadoz Pharmaceuticals LLC
- First approval
- 2026-04-06
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown